In a recent study, researchers led by Beth Weaver from the University of Wisconsin, Madison (UW-M) show that paclitaxel treatment in breast cancer patients increased cell division with chromosome missegregation to induce cytotoxicity.

The axolotl, which can regenerate many of its body parts, was the inspiration for Walking Fish Therapeutics Inc., which just closed on a $50 million series A financing to advance its B-cell therapies for oncology, rare disease, regenerative medicine, autoimmune disease and recombinant antibody production.